Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H28O2 |
| Molecular Weight | 288.4244 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@]34C)[C@@H]1CCC2=O
InChI
InChIKey=RAJWOBJTTGJROA-WZNAKSSCSA-N
InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12,14-16H,3-11H2,1-2H3/t12-,14-,15-,16-,18-,19-/m0/s1
| Molecular Formula | C19H28O2 |
| Molecular Weight | 288.4244 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.drugbank.ca/drugs/DB01561Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/22064602 | https://www.ncbi.nlm.nih.gov/pubmed/3783591 | https://www.ncbi.nlm.nih.gov/pubmed/28733189 | https://www.ncbi.nlm.nih.gov/pubmed/27449532 | https://www.ncbi.nlm.nih.gov/pubmed/10359391
Sources: https://www.drugbank.ca/drugs/DB01561
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/22064602 | https://www.ncbi.nlm.nih.gov/pubmed/3783591 | https://www.ncbi.nlm.nih.gov/pubmed/28733189 | https://www.ncbi.nlm.nih.gov/pubmed/27449532 | https://www.ncbi.nlm.nih.gov/pubmed/10359391
Dihydroandrostenedione (Androstanedione) is a steroid metabolite and a precursor of both testosterone and estrone normally produced by the adrenal gland and gonads and is converted to testosterone through the action of 17β-hydroxysteroid dehydrogenase, which is found in most body tissues. Androstenedione is also produced by some plants and has recently been marketed as a product for increasing blood testosterone concentrations to be used as a natural alternative to anabolic steroid use. However, androstenedione administration during resistance training did not significantly alter the serum testosterone concentration in normotestosterogenic young men. The increased muscle size and strength observed with resistance training were also not augmented with androstenedione administration. The use of androstenedione increased the serum concentrations of estradiol and estrone, suggesting an increased aromatization of the ingested androstenedione and/or testosterone derived from the exogenous androstenedione. The use of androstenedione was associated with decreased levels of HDL-C. These data provide evidence that androstenedione does not enhance adaptations to resistance training and may result in potentially serious adverse health consequences in young men.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1871 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3783591 |
20.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Diagnostic | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| 3-Ketosteroid 9alpha-hydroxylase is an essential factor in the pathogenesis of Mycobacterium tuberculosis. | 2010-01 |
|
| Contributions of active site residues to cofactor binding and catalysis of 3alpha-hydroxysteroid dehydrogenase/carbonyl reductase. | 2010-01 |
|
| Role of S114 in the NADH-induced conformational change and catalysis of 3alpha-hydroxysteroid dehydrogenase/carbonyl reductase from Comamonas testosteroni. | 2009-10 |
|
| Masking effect of anti-androgens on androgenic activity in European river sediment unveiled by effect-directed analysis. | 2009-07 |
|
| Two homologous fungal carbonyl reductases with different substrate specificities. | 2009-03-16 |
|
| Proliferative effect of androst-4-ene-3,17-dione and its metabolites in the androgen-sensitive LNCaP cell line. | 2008-03 |
|
| Mechanism of proton transfer in the 3alpha-hydroxysteroid dehydrogenase/carbonyl reductase from Comamonas testosteroni. | 2007-11-23 |
|
| Androgen metabolism via 17beta-hydroxysteroid dehydrogenase type 3 in mammalian and non-mammalian vertebrates: comparison of the human and the zebrafish enzyme. | 2005-10 |
|
| Characterization of 17alpha-hydroxysteroid dehydrogenase activity (17alpha-HSD) and its involvement in the biosynthesis of epitestosterone. | 2005-07-14 |
|
| Inhibition of 3alpha-hydroxysteroid dehydrogenase (3alpha-HSD) activity of human lung microsomes by genistein, daidzein, coumestrol and C(18)-, C(19)- and C(21)-hydroxysteroids and ketosteroids. | 2005-07 |
|
| Persistence and pathways of testosterone dissipation in agricultural soil. | 2005-04-22 |
|
| Human liver S9 fractions: metabolism of dehydroepiandrosterone, epiandrosterone, and related 7-hydroxylated derivatives. | 2005-04 |
|
| Mechanistic roles of Ser-114, Tyr-155, and Lys-159 in 3alpha-hydroxysteroid dehydrogenase/carbonyl reductase from Comamonas testosteroni. | 2005-02-04 |
|
| 5alpha-reductase in human embryonic kidney cell line HEK293: evidence for type II enzyme expression and activity. | 2005-02 |
|
| Oxidative 3alpha-hydroxysteroid dehydrogenase activity of human type 10 17beta-hydroxysteroid dehydrogenase. | 2003-11 |
|
| Metabolism of estrogens and androgens by scleractinian corals. | 2003-11 |
|
| 5alpha-reduced C21 steroids are substrates for human cytochrome P450c17. | 2003-10-15 |
|
| Inclusion complexes of ketosteroids with beta-cyclodextrin. | 2003-04 |
|
| 13-cis-retinoic acid competitively inhibits 3 alpha-hydroxysteroid oxidation by retinol dehydrogenase RoDH-4: a mechanism for its anti-androgenic effects in sebaceous glands? | 2003-03-28 |
|
| Effects of androgens on aromatase activity and 11C-vorozole binding in granulosa cells in vitro. | 2003-03 |
|
| Androgen inactivation in human lung fibroblasts: variations in levels of 17 beta-hydroxysteroid dehydrogenase type 2 and 5 alpha-reductase activity compatible with androgen inactivation. | 2002-08 |
|
| An assessment of in vitro androgenic activity and the identification of environmental androgens in United Kingdom estuaries. | 2002-07 |
|
| Characterization of the oxidative 3alpha-hydroxysteroid dehydrogenase activity of human recombinant 11-cis-retinol dehydrogenase. | 2001-06-11 |
|
| Searching for the physiological function of 17beta-hydroxysteroid dehydrogenase from the fungus Cochliobolus lunatus: studies of substrate specificity and expression analysis. | 2001-01-22 |
|
| Structure-function aspects and inhibitor design of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3). | 2001-01-22 |
|
| Synthesis of testosterone and 5alpha-androstanediols during nutritionally stimulated gonadal growth in Lytechinus variegatus lamarck (Echinodermata:Echinoidea). | 1998-08 |
|
| Sleep deprivation and adaptive hormonal responses of healthy men. | 1989 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10359391
During weeks 1, 2, 4, 5, 7, and 8, the men were randomized to either androstenedione, 300 mg/d (n = 10), or placebo (n = 10).
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24169035
Ishikawacells were treated with increasing concentrations of A4 (Androstanedione) (0-1000 pmol) for 4 days. Cell proliferation was measured by the (4,5-dimethylthiaxol-2-yi)-2,5-diphenyltetraxolium bromide (MTT) assay. Apoptosis was analyzed through Annexin-V/propidium iodide (PI) staining and flow cytometry: 17β-hydroxy steroid dehydrogenase type 1 (17β-HSD1) and aromatase mRNA expression was measured by reverse transcription-polymerase chain reaction (RT-PCR). Western blotting was used to detect cell signaling expressions of Akt/MAPK. A4 treatment (1 nM) decreased cell proliferation and increased apoptosis, as demonstrated by MTT and flow cytometry or related gene expression. The cellular responses induced by A4 treatment were mediated by activation of the Akt and MAPK signaling pathway. Treatment had no effect on 17β-HSD1 and aromatase expression.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:55:14 GMT 2025
by
admin
on
Mon Mar 31 17:55:14 GMT 2025
|
| Record UNII |
2KR72RNR8Z
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
DEA NO. |
4000
Created by
admin on Mon Mar 31 17:55:14 GMT 2025 , Edited by admin on Mon Mar 31 17:55:14 GMT 2025
|
||
|
NCI_THESAURUS |
C2289
Created by
admin on Mon Mar 31 17:55:14 GMT 2025 , Edited by admin on Mon Mar 31 17:55:14 GMT 2025
|
||
|
CFR |
21 CFR 862.1430
Created by
admin on Mon Mar 31 17:55:14 GMT 2025 , Edited by admin on Mon Mar 31 17:55:14 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
846-46-8
Created by
admin on Mon Mar 31 17:55:14 GMT 2025 , Edited by admin on Mon Mar 31 17:55:14 GMT 2025
|
PRIMARY | |||
|
9897
Created by
admin on Mon Mar 31 17:55:14 GMT 2025 , Edited by admin on Mon Mar 31 17:55:14 GMT 2025
|
PRIMARY | |||
|
15994
Created by
admin on Mon Mar 31 17:55:14 GMT 2025 , Edited by admin on Mon Mar 31 17:55:14 GMT 2025
|
PRIMARY | |||
|
60796
Created by
admin on Mon Mar 31 17:55:14 GMT 2025 , Edited by admin on Mon Mar 31 17:55:14 GMT 2025
|
PRIMARY | |||
|
DTXSID80233576
Created by
admin on Mon Mar 31 17:55:14 GMT 2025 , Edited by admin on Mon Mar 31 17:55:14 GMT 2025
|
PRIMARY | |||
|
DB01561
Created by
admin on Mon Mar 31 17:55:14 GMT 2025 , Edited by admin on Mon Mar 31 17:55:14 GMT 2025
|
PRIMARY | |||
|
Androstanedione
Created by
admin on Mon Mar 31 17:55:14 GMT 2025 , Edited by admin on Mon Mar 31 17:55:14 GMT 2025
|
PRIMARY | |||
|
C107155
Created by
admin on Mon Mar 31 17:55:14 GMT 2025 , Edited by admin on Mon Mar 31 17:55:14 GMT 2025
|
PRIMARY | NCIT | ||
|
212-685-5
Created by
admin on Mon Mar 31 17:55:14 GMT 2025 , Edited by admin on Mon Mar 31 17:55:14 GMT 2025
|
PRIMARY | |||
|
22542
Created by
admin on Mon Mar 31 17:55:14 GMT 2025 , Edited by admin on Mon Mar 31 17:55:14 GMT 2025
|
PRIMARY | |||
|
222865
Created by
admin on Mon Mar 31 17:55:14 GMT 2025 , Edited by admin on Mon Mar 31 17:55:14 GMT 2025
|
PRIMARY | |||
|
2KR72RNR8Z
Created by
admin on Mon Mar 31 17:55:14 GMT 2025 , Edited by admin on Mon Mar 31 17:55:14 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> METABOLITE |
IN VITRO
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|